The lack of a specific diagnostic marker of the IHSS disease spectrum previously has interfered with attempts to characterize this unusual cardiomyopathy more completely. However, we recently identified a characteristic anatomic abnormality, present in patients with or without obstruction, that can be detected reliably and easily by a noninvasive technic.'7 This abnormality also has been described at necropsy,18 and we believe it provides a unifying link for the entire IHSS disease spectrum. The following summarizes some of our recent observations that offer insights into the etiology, pathophysiology, and course of this disorder. These observations also have led us to adopt a new name for the disease.
The characteristic abnormality of all patients meeting the clinical criteria for IHSS is asymmetric septal hypertrophy (ASH). ASH, detected echocardiographically, is defined by a ventricular septum that is disproportionately thickened compared to the posterior-basal left ventricular free wall. We found a septal-posterior free wall ratio greater than 1.3 in every one of 15 patients with typical IHSS;17 in contrast, the septal-posterior free wall ratio was less than 1.3 in normal subjects, patients with fixed left ventricular outflow obstruction, and in essentially every patient with a wide variety of other forms of acquired and congenital heart disease including dilated (congestive) cardiomyopathy and hypertensive heart disease. Occasionally some patients with severe chronic rightsided pressure elevations (i.e. valvular pulmonic stenosis, primary pulmonary hypertension) may also have echocardiographic evidence of disproportionate septal thickening. Such patients, however, can be distinguished easily on the basis of clinical and echocardiographic criteria. These observations have recently been extended to include 827 over 75 patients with IHSS. In every case, the septal-free wall ratio exceeded 1.3.
To determine whether ASH was limited to patients with obstruction, additional echocardiograms were recorded from a large number of symptomatic patients with nonobstructive IHSS (symptomatic patients with clinical evidence of a cardiomyopathy, a small left ventricular cavity, no left ventricular outflow obstruction, and no evidence of other systemic diseases). ASH was found in every such patient we studied.'9 These echocardiographic findings are consistent with several necropsy series which demonstrated that patients with IHSS characteristically have disproportionate thickening of the ventricular septum. '8' 20-23 The disproportionate thickening also was observed by Dr. William Roberts to be present in patients with IHSS in whom no left ventricular outflow gradient was present at catheterization in the absence of provocative maneuvers. 18 Numerous groups have demonstrated that IHSS appears to be genetically transmitted in some families. 8, 21, 24 In others, the disease is thought to be sporadic since no evidence of IHSS can be found.8' 25 One major difficulty in these studies is the criteria used to identify involved individuals. Some have used rigid criteria (catheterization documentation, typical obstructive murmur) while others use less rigid criteria (abnormal ECG, any murmur, suspicion of cardiac symptoms). The features often used to determine whether disease is present are specific for obstructive patients but cannot detect those individuals without obstruction. Thus, even though some investigators feel that the disease must be inherited,10 they have been able to document familial involvement in only 30-40% of patients with IHSS.8. 10, 23 Having demonstrated the sensitivity of echocardiography in detecting a specific marker of the IHSS spectrum, we undertook a study to reevaluate the familial incidence of this disease. Thirty consecutive families of patients with IHSS admitted to the Cardiology Ward of the National Heart and Lung Institute were studied.26 We obtained either echocardiographic, catheterization, or necropsy data on 111 of 159 available first-degree relatives. Diagnostic echocardiograms were recorded in 97 of 103 attempts. ASH was demonstrable in at least one first-degree relative in all but two of the 30 families (in these two families, we had the opportunity of studying only one and two first-degree relatives, respectively). Several of the affected first-degree relatives were asymptomatic, had normal electro-cardiograms, and had little or no evidence of heart disease on physical examination. Others carried a clinical diagnosis of idiopathic myocardial hypertrophy.5 ASH was found in an equal percentage in both sexes; the segregation ratio was close to 0.5.
These findings indicate that ASH: (1) is genetically transmitted as an autosomal dominant trait; (2) exists in a preclinical form; and (3) does not occur sporadically.
Since the family study demonstrated that a large number of patients have inherited the anatomic defect but remain asymptomatic, it is necessary to expand the clinical concept of the IHSS-disease spectrum. 19 At one end of the spectrum are patients in whom the sole manifestation of the disease appears to be mild thickening of the ventricular septum seen on echocardiograms. Such individuals may remain asymptomatic throughout several decades; in fact, we have detected individuals with asymptomatic ASH who are over 70 years of age. In such patients, there is no evidence of disease progression. In other patients with ASH, cardiac symptoms develop at highly variable rates in the absence of left ventricular outflow obstruction. These symptoms are presumably due to impaired ventricular contractile function and reduced diastolic compliance. In a third subgroup of patients with ASH, symptoms appear in association with left ventricular outflow obstruction. Progression of symptoms in this subgroup is also variable. Despite the different hemodynamic presentation caused by the outflow obstruction, it is of interest that patients without outflow obstruction cannot be distinguished symptomatically from those patients with typical obstructive IHSS.19 Specifically, angina, presyncope, and syncope occur frequently regardless of the presence or absence of obstruction. Thus, we conclude that ASH is the common feature of a group of patients whose clinical presentation extends from asymptomatic individuals, to symptomatic patients without outflow obstruction, to symptomatic individuals with typical obstructive IHSS.
Why some patients with ASH develop left ventricular obstruction and others do not is unclear.
Recently, the outflow obstruction has been demonstrated unequivocably to be the result of systolic narrowing of the left ventricular outflow tract caused by apposition of the anterior leaflet of the mitral valve with the markedly hypertrophied ventricular septum.27 This narrowing is due to an abnormal forward movement of the anterior mitral leaflet. It has been s-uggested that the anterior motion is due either to a Venturi effect28 or to traction Circulation, Volume XLVII, April 1973 on the mitral leaflets by papillary muscles malaligned by the massively hypertrophied septum. '8' 29, 30 Support for the first suggestion can be derived mathematically, but a critical experiment to test the derivation in patients has not been devised. The latter hypothesis is supported by anatomic studies which have revealed that papillary muscles of patients with IHSS examined at necropsy often are displaced by the grossly thickened septum. '8 In addition, echocardiographic studies31 have demonstrated that, compared to normal, the mitral valve in patients with ASH is located in a more anterior position at the onset of systole (i.e. prior to ejection), a finding also compatible with a tethering effect. Regardless of whether one or a combination of both hypotheses is correct, a major determinant of the development of outflow obstruction in a given patient seems likely to be the location and degree of septal hypertrophy.
Although we have consistently observed that the ventricular septum is disproportionately thickened in all patients with ASH regardless of the presence or absence of obstruction, one of the important questions relating to the ultimate prognosis of patients is whether the basic myopathic process is relatively localized or is diffusely distributed. In an echocardiographic study of 37 patients with ASH, we found the posterior-basal free wall was normal in thickness in 12 of 13 patients without left ventricular outflow obstruction; in patients with outflow obstruction, however, posterior-basal free wall thickening was present in 19 of 24, and similar in extent to that of patients with fixed left ventricular outflow obstruction of other etiologies. 32 These observations suggested that the myopathic process might be limited to the ventricular septum with the free wall thickened in response to outflow obstruction. Further observations of the distribution of the gross anatomic and ultrastructural abnormalities, however, indicate that the situation is more complex.
Necropsy studies, performed in collaboration with Roberts, revealed that the hearts of all patients whose disorder fell within the IHSS spectrum had septal hypertrophy, which was considerably greater than any other portion of the ventricle. When these patients were subdivided according to the premortem outflow gradient, we noted that hearts from individuals with typical obstructive IHSS had moderate, uniform thickening of the entire left ventricular free wall, including the posterior-basal portion (as indicated by echocardiography). All Circulation, Volume XLVII, April 1973 hearts from patients who at premortem catheterization had no outflow obstruction exhibited a puzzling nonuniform distribution of free wall thickening. The posterior-basal region, however, was invariably spared, a finding again compatible with our echocardiographic observations. Thus, although the thickness of the posterior-basal free wall appears to be normal in the patient without outflow obstruction, it is also clear that considerable nonuniform thickening of other portions of the left ventricular free wall may occur.
We also have investigated the ultrastructural characteristics of the myocardium of several patients with ASH to determine whether pathologic changes are limited to the ventricular septum or are more diffusely distributed. In collaboration with Dr. Barry Maron, light and electron microscopic studies were carried out on biopsy specimens obtained from eight patients with obstructive ASH (typical IHSS) undergoing surgical myectomy and two patients with nonobstructive ASH.32 Morphologic abnormalities were grouped into two categories: (1) intracellular abnormalities (disarray of myofibrils and myofilaments); and (2) cell-to-cell abnormalities (disorganization of muscle cells, abnormal cell contacts). Septal biopsies were obtained in eight obstructive patients and one of two nonobstructive patients. In all specimens, many muscle cells were markedly enlarged, bizarrely shaped, and demonstrated extensive intracellular and cell-to-cell abnormalities. This corroborates a previous report by Dr. Victor Ferrans from this Institute.33 However, an interesting pattern emerged when biopsies from portions of myocardium other than the septum were analyzed (left ventricular apex and left ventricular posterior wall). Mild-to-moderate cell enlargement, indicative of hypertrophy, was present in all specimens. In the obstructive patients, no cell-to-cell alterations were present and intracellular abnormalities were observed in only three of eight patients. In contrast, intracellular changes in both nonobstructive patients and mild-to-moderate cellto-cell abnormalities were present. These findings demonstrate that the morphologic alterations in both obstructive and nonobstructive ASH are much more prevalent in the septum. Of particular interest, however, is the suggestion that involvement of the left ventricular free wall by the cardiomyopathic process appears to be considerably more extensive in the nonobstructive patients. Such a conclusion must obviously be regarded as tentative until tissue from a greater number of such patients is studied.
A priori, it is impossible to say whether the muscle cell hypertrophy, intracellular abnormalities (mvofibrillar and myofilament disarray) or cell-tocell abnormalities (cellular disorganization and abnormal cell contact) are primary, since any one defect might induce the others. It is also possible that two or even all of the defects are primary. However, the cellular hypertrophy and the intracellular features are not specific for patients with IHSS and are commonly found in patients with other forms of left ventricular hypertrophy. The cell-to-cell defects, on the other hand, are more specific for IHSS and therefore may be a better marker of the primary myopathy. Whatever the fundamental defect is, it raises the important questions of why a cell hypertrophies and how a cell aligns during embryogenesis. Further study of this disease may significantly add to our knowledge of normal and abnormal cardiac morphogenesis.
Although the family data indicate that the gross anatomic abnormalities are genetically transmitted,26 several aspects of the pathophysiology of these defects are unclear. For instance, why is the septum asymmetrically hypertrophied in every patient? Why is the free wall nonuniformly thickened in the nonobstructive patients? What is the mechanism of the uniform thickening of the free wall in the typical obstructive (IHSS1) patient?
To explain the unusual distribution of thickening in this disease, we are considering two working hypotheses. Both depend on the idea that ASH is inherited with the genetic abnormality expressed as altered cell morphology, impaired function, or both. The first hypothesis states that the morphologic defect may appear at any time from embryogenesis to death. The basic defect is due to abnormal DNA which is present in each cardiac muscle cell. However, the morphologic and functional expression of this genetic defect may become apparent at different rates in different portions of the ventricle. The second hypothesis differs from the first in that, while the abnormal gene is expressed in some portions of the ventricle leading to morphologic and functional evidence of the myopathy, other regions are normal and remain normal throughout life. Implicit in the first hypothesis is the concept that every patient is at risk of developing cardiac symptoms due to progressive diffuse deterioration of myocardial cell function. Although the second hypothesis is also compatible with progressive deterioration, it would not be the result of a functional impairment of all of the left ventricle, but rather to altered cell function of the affected cells with persistence of normality in the remainder. In other words, in some patients the genetic defect will express itself diffusely, eventually causing an incapacitating myopathy; in others, expressioni of the defect will be restricted (perhaps largely to the septum in some, more diffusely in others), thus causing minimal to severe functional impairment, depending on the extent of involvement. Left ventricular outflow obstruction, of course, may complicate the clinical picture. Regardless of which basic pathogenic mechanism is responsible for the myopathy, it is clear that the ventricular septum is preferentially involved. This may be due to the complexity of septal development during embryogenesis, or to the different mechanical stresses the septum is subjected to during cardiac contraction.
These hypotheses have clinical implications relative to the surgical management of patients whose disorder lies at one end of the IHSS disease spectrum, i.e., typical obstructive IHSS. Septal myectomy has been shown to be effective in relieving both left ventricular outflow obstruction and symptoms. 34 If the myopathic process is predetermined genetically to involve the entire ventricle, then the uniform free wall thickening seen in obstructive patients might well be due to the basic myopathy. In this case. it is possible that symptoms will return following initial symptomatic improvement. If, on the other hand, the free wall is thickened largely because of secondary hypertrophy due to left ventricular outflow obstruction (and otherwise is not at all or only minimally involved in the myopathic process), eventual symptomatic deterioration may not be an intrinsic feature of the natural history of this subgroup of patients. In our own experience, we have not observed the return of symptoms in postoperative patients despite follow-up periods for as long as 12 years (unpublished observations). While this does not necessarily support the second hypothesis, it at least indicates that, if a progressive cardiomyopathy involves the free wall in this specific subgroup of patients, it is doing so at a very slow rate.
In conclusion, a cardiac disease exists that has asymmetric septal hypertrophy as its common feature. This disease is genetically transmitted and presents clinically as a continuous spectrum. This spectrum includes asymptomatic individuals, symptomatic patients without outflow obstruction, and symptomatic individuals with typical obstructive Circulation, Volume XLVII, April 1973 IHSS. Ultrastructural observations suggest that the fundamental cardiac defect involves abnormal muscle cell hypertrophy and/or altered cellular morphogenesis. We believe that "asymmetric septal hypertrophy" is the best name for this disease. This name not only provides a concise acronym (i.e., ASH), but also describes an anatomic abnormality that (1) can be detected noninvasively, (2) distinguishes patients with this disease from those with other forms of ventricular dilatation or hypertrophy, (3) provides a terminology independent of outflow obstruction, (4) permits the preclinical identification of affected individuals, and (5) identifies a genetically transmitted defect. 
